Overview of Cardotek-30

What is Cardotek-30?

Cardotek-30 is a veterinary medication specifically developed for the prevention of heartworm disease in dogs. It is a monthly prophylactic treatment designed to eliminate the tissue stages of heartworm larvae, preventing them from developing into adult worms that can cause serious cardiac and pulmonary complications.

Primary Active Ingredient

The active pharmacological component in Cardotek-30 is ivermectin. This compound belongs to the avermectin family, a class of antiparasitic agents that interfere with the nervous system and muscle function of specific parasites. When administered at the recommended preventative dosage, ivermectin targets the larval stages of Dirofilaria immitis (heartworm) acquired from mosquitoes during the previous 30 days.

Therapeutic Goal

The primary objective of using Cardotek-30 is long-term heartworm prevention. Because heartworm disease is a progressive and potentially fatal condition, the medication is used to provide continuous protection by interrupting the parasite's life cycle before it can establish an infection in the heart and lungs.

Formulation and Characteristics

Cardotek-30 is typically produced as an oral chewable tablet. The formulation is designed to be palatable to dogs to facilitate ease of administration. While the primary indication is the prevention of heartworm, the medication specifically addresses the larval transition period, ensuring that any larvae transmitted via insect bites do not reach maturity.

What side effects are possible with Cardotek-30?

Possible Side Effects and Safety Information

The safety profile of Cardotek-30 (Ivermectin and Pyrantel Pamoate) is officially documented by government regulatory authorities, establishing the spectrum of adverse reactions and specific safety considerations. Adverse effects are categorized based on their observation during clinical field trials and through post-approval surveillance.

Adverse Reaction Spectrum

Adverse events reported either in clinical trials or post-approval generally involve the Gastrointestinal System (e.g., vomiting, diarrhea, and anorexia) and the Nervous System (e.g., lethargy, ataxia, muscle tremors, hypersalivation, and seizures). In clinical trials, vomiting and diarrhea were typically observed within 24 hours of administration.

Other adverse reactions reported through post-approval surveillance include pruritus (itching).

Serious Safety Considerations and Limitations

The regulatory label documents specific serious events and safety limitations:

Serious Adverse Reactions: Post-approval reports have included choking or intestinal obstruction. Furthermore, severe neurological signs (including stupor, coma, and death) have been observed when Ivermectin is administered at dose levels significantly higher than recommended in certain Collie breeds.
Population-Specific Notes: The product is restricted to dogs 6 weeks of age and older. Dogs with circulating microfilariae (larval heartworms) may experience a transient, mild hypersensitivity-type reaction (e.g., transient diarrhea) due to the death of the microfilariae following administration.

This information defines the official safety characteristics as determined by regulatory agencies.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Cardotek-30

The official overdose information for this combination product (Ivermectin and Pyrantel embonate) focuses heavily on the neurological risks associated with the Ivermectin component at highly elevated dose levels.

Overdose Scope	Regulatory Description
Documented Overdose Presentations	Overdose symptoms documented in regulatory summaries include Central Nervous System (CNS) effects such as ataxia (unsteadiness), muscle tremors, lethargy, depression, stupor, and seizures. Gastrointestinal effects like vomiting, diarrhea, and hypersalivation may also occur.
Serious / Life-Threatening Outcomes	Severe intoxication is linked to profound neurological depression, potentially leading to coma or death at extreme dose levels, as documented in veterinary safety reports.
Dose-related or Exposure Factors	Toxicity is primarily seen following accidental ingestion of large quantities of the product or exposure to highly concentrated formulations intended for larger animals.
Population-Specific Overdose Notes	Regulatory labeling notes that dogs possessing the MDR1 gene mutation (e.g., Collies and related breeds) are officially recognized as having increased sensitivity to the neurological effects of Ivermectin at elevated doses.
Emergency-Response Statement	The official labeling mandates that in cases of suspected overdose, a physician must be contacted immediately (for human ingestion) or a veterinarian must be consulted immediately (if the animal consumes more than the prescribed amount).

Official Overdose Statements:

In the event of suspected overdose or accidental ingestion by a human, the regulatory instruction is to seek immediate medical attention or call a Poison Control Center for guidance.
Treatment for established intoxication is officially defined as symptomatic and supportive care, as no specific antidote is known for Ivermectin toxicosis.
Management procedures may include the administration of anti-seizure medication, intravenous fluids, and close hospital monitoring, particularly in cases where severe neurological signs are present.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by detailing the anticipated clinical presentation, which is dominated by dose-related neurological toxicity affecting the CNS. Due to the potential for severe, life-threatening outcomes and the lack of a known specific antidote, official labeling uniformly requires immediate professional medical intervention. This necessity for urgent help establishes the core emergency-seeking condition mandated by governmental authorities.

Therapeutic Uses of Cardotek-30

What Cardotek-30 Treats: Main Uses and Benefits

Cardotek-30 is commonly used to help with managing the risk associated with specific parasitic conditions, aligning with a strategy for ongoing health maintenance. The medication may be part of symptomatic management in situations where consistent use is medically appropriate. This medication is applicable in clinical settings that involve acute or disruptive symptom patterns related to the conditions involving episodic or fluctuating manifestations of parasites, which include those that affect the heart and intestines.

The medication supports the animal during periods of heightened risk by easing the overall symptom burden associated with these common infestations. The primary therapeutic domains involve support in situations involving certain distressing symptoms, and assisting with the management of hookworms and roundworms. It assists with maintaining functional stability when symptoms linked to organ-specific functional stress may otherwise become noticeable.

Quick Fact Block

Quick Fact: Focus on: Symptoms that interfere with daily functioning

This medication contributes to improved comfort during periods of heightened risk and is relevant when short-term symptomatic assistance is needed to manage the potential for heightened physiological activity caused by infestation.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cardotek-30 — official regulatory information

Eligibility Scope

Populations for whom use is allowed: The product is approved strictly for use in the Canine species (dogs). This includes pregnant or breeding bitches and stud dogs, for whom a wide margin of safety has been demonstrated at the recommended dose level.
Populations for whom use is contraindicated: Administration is absolutely prohibited for dogs with a known hypersensitivity or allergy to the active ingredients, Ivermectin or Pyrantel.
Age-related eligibility rules: Use is restricted to dogs six weeks of age and older. Puppies younger than this minimum age threshold are formally excluded from use.
Condition-specific eligibility rules: The medicine must not be administered until the dog has been tested and confirmed to be heartworm-negative. Starting the preventive program in a heartworm-positive dog is a pre-treatment exclusion.
Eligibility-related restrictions: For large dogs over 100 lbs (45 kg), eligibility requires administering the appropriate combination of chewables as specified in the labeling.

Eligibility Classifications (High-Level)

Classification Basis: Eligibility is defined by the U.S. Food and Drug Administration (FDA) New Animal Drug Application labeling.
Eligibility Constraints: The primary constraints are the animal's age, species, and a mandatory negative test for existing heartworm infection.

Resulting Eligibility Structure

Official regulatory documents define who can and cannot use this medicine based on four non-negotiable criteria: the animal must be a dog, be at least six weeks old, have a known heartworm-negative status, and possess no known allergy to the formulation's components. The labeled profile explicitly permits use in reproductive animals and establishes the lower age limit for eligibility at six weeks. This framework strictly governs who is approved to receive the medicine, as detailed in the regulatory prescribing information.

What should I know about interactions with other medicines?

Cardotek-30 Interactions with other medicines and products

The official interaction profile for Cardotek-30 is defined by the pharmacokinetic behavior of its active component, Ivermectin, focusing exclusively on substances and conditions that modify its systemic concentration.

Exposure Modification through Transporters and Metabolism

Co-administration with P-glycoprotein (P-gp) inhibitors, such as cyclosporine or ketoconazole, is officially documented to increase the plasma concentration of Ivermectin. This is classified as a transporter-mediated interaction where P-gp inhibition reduces the drug's essential efflux mechanism, resulting in heightened systemic exposure. Similarly, inhibitors of the CYP3A4 enzyme may also alter Ivermectin's metabolic clearance, contributing to the overall pharmacokinetic interaction potential. There are no mandatory timing rules specified, and no drug combinations are formally listed as contraindicated due to an interaction effect.

Food and Population Constraints

A significant drug–food interaction is documented in official sources: the absorption and subsequent bioavailability of Ivermectin are substantially increased when the medication is administered alongside a high-fat meal. This factor must be considered as it leads to elevated plasma exposure. Furthermore, regulatory documents specify that the clinical significance of these exposure-altering interactions is population-dependent. The interaction risk is notably higher in certain dog breeds with a genetically determined deficiency in P-glycoprotein function (MDR1 mutation).

Mechanism of Action

The pharmacological action of Cardotek-30 is defined by the distinct, complementary actions of its two components, Ivermectin and Pyrantel embonate, which simultaneously target distinct biological systems across various nematode species and developmental stages.

Ivermectin acts as a selective modulator of glutamate-gated chloride channels ( GluCl) in the parasite's nerve cells, forcing the channels to remain open. This influx of negative chloride ions leads to hyperpolarization and a complete flaccid paralysis of heartworm larvae and microfilariae, resulting in the cessation of nerve signaling and motor function.

In contrast, Pyrantel embonate acts directly on the somatic muscles of intestinal worms by persistently activating nicotinic acetylcholine receptors ( nAChR). This leads to continuous, excessive muscle contraction, resulting in spastic paralysis that prevents the worms from anchoring to the host's intestinal wall. The Ivermectin mechanism is highly targeted, utilizing GluCl channels unique to invertebrates. Ivermectin is actively transported by the P-glycoprotein efflux pump, which restricts the compound's concentration within the host's central nervous system. The combined effect results in irreversible neuro-muscular disruption and loss of function in susceptible parasitic stages.

Dosage and Administration Information

How to Use Cardotek-30

The usage of Cardotek-30 (a combination of Ivermectin and Pyrantel embonate) follows a standardized, monthly, weight-based oral regimen. This section outlines the administration requirements and procedural timing.

Administration Guidelines

Administration Scope	Requirements
Route of Administration	The product is for oral use via a chewable tablet.
Dosing Schedule	Dosing is weight-based. The tablet strength must be selected to provide a minimum recommended dose of 6 mcg of Ivermectin and 5 mg of Pyrantel (as pamoate salt) per kilogram of the dog's body weight.
Frequency	Administration must occur at monthly intervals (every 30 days).
Contextual Timing	The tablet should be administered with food or immediately after feeding to ensure complete ingestion.
Age Restriction	Use is authorized for dogs 6 weeks of age and older.

Procedural Instructions and Course Duration

Administration follows a specific sequence and timing pattern. The medication must be given within 30 days of the animal's first possible exposure to mosquitoes, and the final dose must be administered within 30 days of the last possible exposure for the season.

To ensure the complete dose is swallowed, the animal should be observed briefly following administration. If a monthly dose is missed or delayed, immediate administration is required, and the standard 30-day schedule should be resumed immediately thereafter. This structure ensures continuous dosing aligned with periods of risk.

Recent Clinical Evidence

Research evidence / Overview of studies for Cardotek-30

Evidence for use in Heartworm Prevention

Research exploring the prevention of canine heartworm disease (Dirofilaria immitis) has been a core focus of the clinical evaluation for this medication. The foundational evidence comes primarily from controlled, randomized laboratory studies where researchers observed the animals under predefined conditions. These pivotal trials were designed to examine whether the product influenced the development of the early larval stage of the parasite into adult heartworms. This model provides a measurement framework used for regulatory purposes.

Complementing these studies are long-term observational studies conducted in field settings. These trials examined the use of the medication in client-owned dogs of diverse breeds and ages over extended periods. In these contexts, research monitored outcomes related to systemic or functional imbalance, such as tracking measurements of heartworm antigen (Ag) levels over time. Studies monitored patterns observed in the animals, and the study data includes reports that examined the combination's performance against a predefined regulatory threshold for parasite development.

Evidence for use in Intestinal Parasite Control

The medication was studied for its use in addressing common intestinal parasites, including specific species of hookworms and roundworms. The evidence for this use relies mainly on controlled laboratory trials where animals had either natural or induced infections. The outcomes monitored were primarily focused on acute parasite burden reduction.

What is still uncertain about Cardotek-30

The existing evidence base highlights what is known, but also what is still uncertain. Findings were mixed in some comparative trials regarding the product's performance against drug-resistant heartworm strains, meaning researchers are still exploring how this resistance affects prevention in the field. Furthermore, the follow-up durations were limited for acute parasite burden reduction studies, meaning there is limited information for long-term outcomes related to maintaining a low parasite burden over multiple cycles. Research does not determine whether an individual animal will respond similarly, and study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Cardotek-30 (FAQ)

Q: How long does it typically take for Cardotek-30 to start working?

Studies related to similar formulations indicate that the active components begin their essential work soon after administration, often within 24 hours. The overall purpose of the medication is to eliminate the heartworm larval stage acquired in the preceding 30 days, thereby providing continuous monthly protection.

Q: Is Cardotek-30 known to cause weight gain?

Weight gain is not officially listed in the adverse reaction spectrum found in regulatory documents based on clinical trials and post-approval surveillance. The commonly reported digestive and nervous system effects include vomiting, diarrhea, and anorexia (loss of appetite).

Q: What happens if I miss a dose of Cardotek-30?

Official administration guidelines state that if a monthly dose is missed or delayed, immediate administration is required. After the delayed dose is administered, the standard 30-day schedule is to be resumed immediately thereafter to maintain continuous protection.

Q: Can Cardotek-30 interact with herbal supplements?

Regulatory documents describe potential interactions with substances that inhibit P-glycoprotein (P-gp), which is a transporter that helps control the concentration of Ivermectin in the body. Since many herbal supplements are known to affect P-gp activity, official information notes this potential for interaction.

Q: Is there a generic version of Cardotek-30 available?

Cardotek-30 is a specific brand name for a combination product containing Ivermectin and Pyrantel pamoate. The active ingredient combination, Ivermectin/Pyrantel, is widely available under various brand names and generic listings approved by regulatory bodies.

Q: Why is the number '30' in the name Cardotek-30?

Official documents link the product to a 30-day cycle of prevention. The medication works by eliminating the tissue stage of heartworm larvae for a period of one month (30 days) after potential exposure, which aligns with the required monthly administration schedule.

Q: Does Cardotek-30 cure the condition it treats, or just manage it?

Official documents define the product’s indication as the prevention of heartworm disease. It works by eliminating the larval stage of the parasite. Official information specifies that the medication is not effective against adult heartworms and is therefore not considered a cure for an existing adult heartworm infection.

Q: Will Cardotek-30 affect my ability to drive or operate machinery?

Official documents clearly state that this product is formulated specifically for veterinary use in dogs only and is not approved or intended for human use. Official warnings emphasize keeping the product out of the reach of children and pets.

Q: How long can a person safely stay on Cardotek-30?

Regulatory administration guidelines specify that the medication must be given at monthly intervals (every 30 days). The course duration is typically related to the animal’s period of possible exposure to mosquitoes, often involving an extended seasonal or year-round regimen depending on risk factors.

Q: What is the difference between Cardotek-30 and Cardotek-60?

In many combination products of this type, the number in the name is commonly used to refer to the intended weight class of the animal. A '30' dose is regulated for a lower weight range, while a '60' dose is regulated for a heavier weight class, reflecting the weight-based dosing requirements.

Q: Is it possible to become dependent on Cardotek-30?

Regulatory documents classify this medication as an anthelmintic and do not list terms like 'dependence,' 'addiction,' or 'abuse potential' within the official warnings, precautions, or safety sections.

Q: What should I do if I experience a mild side effect from Cardotek-30?

Official documents state that if side effects are observed in the animal, such as vomiting, stomach upset, or unsteadiness, immediate contact with a veterinarian is noted as appropriate. For human ingestion, official information specifies that individuals should contact a physician or a Poison Control Center.

Q: Does Cardotek-30 require special monitoring or blood tests?

Yes, official precautions state that all dogs must be tested and confirmed heartworm-negative before starting the preventive treatment. Additionally, if an administration is delayed by more than 8 weeks, it is recommended to contact a veterinarian for guidance on potential re-testing.

Q: What happens if I stop taking Cardotek-30 suddenly?

Stopping the medication suddenly could result in the animal losing its required monthly protection against the development of heartworm disease. Continuous monthly administration is required to eliminate the larval heartworm stage and maintain prevention.

Q: Are there any lifestyle changes recommended when taking Cardotek-30?

Regulatory documents do not recommend general lifestyle changes but do specify one key administration condition: the product must be administered alongside a high-fat meal to ensure proper absorption of the active ingredient, Ivermectin.

Q: Does Cardotek-30 contain any ingredients that cause allergic reactions?

The product is not to be used in dogs with a known hypersensitivity or allergy to the active ingredients: Ivermectin or Pyrantel. Official labeling does not list other inactive ingredients as known allergens.

Q: Can I drink alcohol in moderation while taking Cardotek-30?

This product is specifically manufactured and regulated for veterinary use in dogs only. Regulatory documents contain no information or guidance regarding the interaction of this product with human alcohol consumption.

Q: Does Cardotek-30 affect fertility?

Safety studies have established a wide margin of safety at the recommended dose level, and the product is approved for use in pregnant or breeding bitches and stud dogs.

Q: Does Cardotek-30 have a 'black box warning' in the US?

Regulatory documents for this product in the US do not contain the specific feature known as a Boxed Warning, which is sometimes referred to as a 'black box warning.' The label does include dedicated Warnings and Precautions sections for important safety information.

Q: Is Cardotek-30 a controlled substance?

The official label includes a cautionary statement that Federal law restricts this drug to use by or on the order of a licensed veterinarian. This classifies it as a prescription veterinary drug, but it is not scheduled as a controlled substance under US drug regulations.

Q: What is the maximum duration for seeing a positive effect from Cardotek-30?

As a preventive medication, the primary effect is the continuous elimination of the heartworm larval stage acquired in the preceding 30 days. The expected positive effect is the continuation of protection, which is maintained through continuous, 30-day administration.

Q: What is the risk of a drug interaction with common vitamins?

Official safety information notes that in clinical trials, many commonly used compounds, including vitamins, have been administered alongside this combination product as part of a heartworm prevention program. There were no specific, noted interactions reported in that context.

Q: Does Cardotek-30 work differently for older people compared to younger adults?

The product is formulated exclusively for use in dogs. There are no regulatory documents addressing its effects in different age groups of humans, nor is human use permitted.

How should Cardotek-30 be stored and disposed of?

Storage Conditions and Disposal Instructions

Official regulations define specific conditions for the storage and disposal of Cardotek-30 to ensure product stability and environmental safety.

Item	Official Regulatory Requirement
Storage Temperature	Store at controlled room temperature between 59°F and 86°F (15°C and 30°C).
Protection	Must be protected from excessive heat and moisture.
Safety	Keep the product strictly out of the reach of children and pets.

The official storage profile mandates maintenance within this temperature range and protection from prohibited environments. The disposal instructions require that unused or expired product must be managed in accordance with local regulations. Furthermore, due to the environmental risk posed by the active substance, Ivermectin, the medication must not be discarded into watercourses or released into the general environment.

Cardotek-30